This trial will study a new cream to treat plaque psoriasis. The cream will be applied once a day for 24 weeks.
- Chronic Plaque Psoriasis
1 Primary · 7 Secondary · Reporting Duration: 24 weeks
1 Treatment Group
ARQ-151 Cream 0.3%
1 of 1
285 Total Participants · 1 Treatment Group
Primary Treatment: Topical roflumilast · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 2 - 11 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|Arcutis Biotherapeutics Clinical Site 217||50.0%|
|Arcutis Biotherapeutics Clinical Site 238||50.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||50.0%|
How many prior treatments have patients received?
Frequently Asked Questions
Are patients being actively sought for this experiment?
"This particular clinical trial, as recorded on the website clinicaltrials.gov, is not currently looking for patients to participate. This study was originally posted on February 12th 2020 and updated November 9th of 2022. There are, however, 189 other trials that are recruiting patients." - Anonymous Online Contributor
Does the age limit for this test extend past 25 years old?
"According to the eligibility requirements listed on this clinical trial, patients must be aged 2-11. There are a total of 33 clinical trials for children under 18 and 160 for adults over 65 years old." - Anonymous Online Contributor
What are the possible side effects of using Topical roflumilast?
"Topical roflumilast has undergone multiple rounds of testing and has been proven effective, making it a safe choice with a score of 3." - Anonymous Online Contributor
How many people are being allowed to participate in this trial?
"Unfortunately, this trial is not looking for new patients at the moment. The listing was first created on February 12th 2020 and edited most recently on November 9th 2022. However, there are presently 179 other trials actively recruiting psoriasis patients and 10 topical roflumilast studies also admitting participants." - Anonymous Online Contributor
How can I sign up for this opportunity to participate in this research?
"Eligibility for this psoriasis study requires that patients be aged 2-11. Up to 285 individuals will be enrolled in the clinical trial." - Anonymous Online Contributor
How many different medical centers are conducting this experiment?
"83 clinical sites are running this study, including Arcutis Biotherapeutics Clinical Site 509 in Fountain Valley, Pennsylvania, Arcutis Biotherapeutics Clinical Site 511 in Rancho Santa Margarita, Texas, and Arcutis Biotherapeutics Clinical Site 113 in Exton, North Carolina." - Anonymous Online Contributor
Is roflumilast the first medication of its kind?
"Roflumilast was first trialed in 2018 at Mays Cancer Center, UT Health San Antonio. Since then, there have been 47 completed studies with roflumilast. Presently, 10 clinical trials are recruiting patients with several of these based in Fountain Valley, Pennsylvania." - Anonymous Online Contributor